Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

1.32
-0.0150-1.13%
Volume:935.89K
Turnover:1.22M
Market Cap:445.15M
PE:-5.16
High:1.34
Open:1.32
Low:1.29
Close:1.33
52wk High:2.73
52wk Low:1.00
Shares:338.52M
Float Shares:327.56M
Volume Ratio:0.61
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-26.89
PE(LYR):-5.82

Loading ...

Ocugen Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Mar 26

Ocugen: Encouraging Phase 2 OCU410 Data in Geographic Atrophy Underpin Buy Rating and Long-Term Upside Potential

TIPRANKS
·
Mar 26

Is Ocugen (OCGN) Pricing Make Sense After Its Volatile Multi‑Year Share Price Swings

Simply Wall St.
·
Mar 25

Ocugen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Ocugen price target raised to $10 from $7 at H.C. Wainwright

TIPRANKS
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24

Ocugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy

MT Newswires Live
·
Mar 24

BUZZ- Ocugen rises as gene therapy slows vision loss in advanced eye disease trial

Reuters
·
Mar 24

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

TIPRANKS
·
Mar 24

Ocugen reports 31% lesion growth reduction at 12 months in Phase 2 ArMaDa trial of OCU410 for geographic atrophy

Reuters
·
Mar 24

Ocugen Inc - to Initiate Ocu410 Phase 3 Registrational Trial in Q3 2026

THOMSON REUTERS
·
Mar 24

Ocugen Announces Topline 12-Month Data From Phase 2 Armada Clinical Trial Evaluating Ocu410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS
·
Mar 24

Ocugen Inc - No Serious Adverse Events Related to Ocu410 Reported to Date

THOMSON REUTERS
·
Mar 24

Ocugen’s OCU410 Data And Index Move Test New Investor Interest

Simply Wall St.
·
Mar 24

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
Mar 24

Ocugen to webcast Phase 2 ArMaDa trial data for OCU410 in geographic atrophy on March 24, 2026

Reuters
·
Mar 23

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

GlobeNewswire
·
Mar 23

TTD, OCGN, STZ, VRTX, LCID Trending With Analysts

TIPRANKS
·
Mar 21

Ocugen Gains $15 Million, Extends Cash Runway to 2027

TIPRANKS
·
Mar 20

Ocugen raises USD 15 million from partial exercise of warrants for 10 million shares

Reuters
·
Mar 20